

**AN IMPLANTABLE FLUID MANAGEMENT SYSTEM FOR  
THE REMOVAL OF EXCESS FLUID**

**CROSS-REFERENCE TO RELATED APPLICATIONS**

**[0001]** This is a continuation of application No. 10/700,863, filed 3 November 2003, incorporated by reference herein in its entirety.

**FIELD OF THE INVENTION**

**[0002]** The invention is generally in the field of medical devices. More particularly, it relates to implantable pump-assisted drainage devices, e.g., for transvesicluar drainage, capable of draining fluid from a bodily cavity into another bodily cavity, such as a bladder.

**BACKGROUND OF THE INVENTION**

**[0003]** There are a variety of conditions which result in pathologic chronic collection of bodily fluids within the body of a person. Chronic pericardial effusions, normopressure hydrocephalus, hydrocephalus, chronic pulmonary effusion, pulmonary edema, and ascites are but a few of the conditions in which chronic fluid collections persist and result in increased morbidity and mortality.

**[0004]** These types of conditions currently are treated typically by one of three methods: 1) external drainage with a high-risk of infection and long-term requirement for multiple punctures, 2) drainage to another body cavity, or 3) treatment with various drugs. For pericardial effusions and hydrocephalus of all types, the treatment of choice is typically drainage to another region of the body. For pericardial effusions this entails a

1 pericardial window, a highly invasive procedure in which a large section of the external  
2 heart cavity is removed. For hydrocephalus, the treatment typically involves the use of a  
3 ventriculo-peritoneal shunt draining the cerebrospinal fluid into the peritoneal cavity.  
4 This device frequently becomes clogged due to the proteinaceous environment of the  
5 peritoneal cavity and requires removal or revision.

6 **[0005]** One problem which may arise with the chronic collection of bodily fluids  
7 is ascites, which is a highly debilitating complication associated with many medical  
8 conditions including liver failure and congestive heart failure. Untreated ascites can  
9 result in respiratory compromise, compression of the inferior vena cava (a vital blood  
10 vessel) and spontaneous bacterial peritonitis (a life-threatening condition). In order to  
11 treat chronic ascites, medicine has turned to both drugs and surgery.

12 **[0006]** The drugs required to treat ascites are typically long-term and frequently  
13 result in complications. The most common pharmaceutical treatment of ascites involves  
14 the use of diuretics to remove fluid from the patient's body through their urine. The  
15 difficulty with this treatment, though, is that fluid is removed from the entire body,  
16 including the circulating volume of blood, and can result in excessive loss of fluid  
17 required to perfuse the vital organs of the human body. Thus, even with frequent  
18 application, the medicines frequently fail. In such cases, surgical, or invasive, procedures  
19 are indicated.

20 **[0007]** Currently the most common surgical treatment is paracentesis. In  
21 paracentesis, the peritoneal fluid is drained through the abdominal wall via the insertion  
22 of a needle through the abdominal wall into the peritoneal cavity. This procedure is only  
23 a temporary solution as the ascites quickly refills the peritoneal cavity in most chronic

1 conditions. Furthermore, repeated paracenteses places the patient at increased risk for a  
2 life-threatening infection of their peritoneal cavity. Other surgical/invasive procedures  
3 typically involve treatment of the cause of the ascites (for example, the Transjugular  
4 Intrahepatic Portosystemic Shunt) but these measures also frequently result in  
5 complications, which are often serious and are thus performed infrequently.

6 **[0008]** Many of the existing commercially available devices provide little  
7 improvement over the intermittent punctures of paracentesis and result in increased rates  
8 of infection or other complications if left in place for any length of time. Therefore, there  
9 is a need for a device which effectively reduces the need for repeated punctures or  
10 abdominal incisions and thereby reduces the risk of serious infection.

#### 11 SUMMARY OF THE INVENTION

12 **[0009]** An implantable fluid management system, as described herein, may  
13 typically comprise a first tube member having a first end, a second end, and a length  
14 which defines a lumen therethrough and having at least one opening at the first end or  
15 along the length, a second tube member having a first end, a second end, and a length  
16 which defines a lumen therethrough, a pump fluidly coupled to the first tube member and  
17 the second tube member for urging fluid through each tube member, and a shunt  
18 connected to the second end of the second tube member, wherein the shunt is adapted to  
19 anchor the second end of the second tube member to a wall of a hollow body organ in a  
20 fluid-tight seal.

21 **[0010]** This system may avoid difficulties typically associated with the current  
22 therapies. For instance, in the treatment of chronic ascites, the devices of the system may  
23 allow for the removal of peritoneal fluid without 1) serious complications generally

1 associated with use of pharmaceuticals, 2) inconvenience, for example, the substantial  
2 costs and the increased risk of infection associated with frequent paracenteses, or 3)  
3 multiple severe complications associated with more invasive and risky surgical  
4 operations to treat the cause of ascites. The implantable fluid management system may  
5 be utilized for chronic excess fluid drainage from one bodily cavity to a second bodily  
6 cavity, e.g., a urinary bladder. An implantable electromechanically powered and/or  
7 magnetically coupled vesicular pump may be utilized to permit assisted flow of the  
8 excess fluid collections into the bladder. This flow may be directed to be uni-directional  
9 through the system.

10 **[0011]** One particular variation of the system may be used as an ascites drainage  
11 device. For instance, the device of the system may be used for peritoneovesicular  
12 drainage of the peritoneal fluid from the peritoneal cavity into, e.g., the bladder. The  
13 drainage of the fluid may be uni-directional through the system. To urge the fluid  
14 through the fluid management system, a pump which is fully implantable may be utilized  
15 with the system to transfer excess fluid from a variety of locations in the human body, for  
16 instance, the peritoneal cavity, to another region within the body, for instance, the urinary  
17 bladder, for the treatment of chronic fluid collections.

18 **[0012]** The system, including the pump and/or tubular members, may be  
19 configured to enable fluid flow in only one direction into, e.g., the bladder, to prevent the  
20 reflux of urine or other fluids into the area being drained while still allowing the drainage  
21 of the fluid into the bladder. This uni-directional configuration may be achieved through  
22 incorporation of a uni-directional valve in the lumen of the tubing or through the use of a  
23 uni-directional pump which may also be prevented from being driven in reverse.

1 **[0013]** The device may include at least two distinct flexible tubular members each  
2 defining at least one lumen therethrough. One tubular member may be used for drawing  
3 fluid from the region to be drained into or through the pump while the other tube may be  
4 used for channeling the fluid from the pump into the hollow body organ such as the  
5 bladder. The tube for drawing the excess fluid from the the body cavity may contain or  
6 define at least one opening, and may preferably define multiple perforations, and/or anti-  
7 clogging mechanisms in the region of the fluid intake. This tubular member may also  
8 optionally incorporate chemical- or pressure-sensing elements to trigger and/or prevent  
9 activation of the pump under specific circumstances. The tubular member carrying the  
10 pumped fluid to the bladder may feature an anchoring mechanism such as a shunt  
11 mentioned above (e.g., a flange, pigtail coil, etc.) and may optionally be coated with a  
12 hydrophilic material to prevent encrustation. The tip of this tubing may also optionally  
13 incorporate chemical- or pressure-sensing elements to trigger and/or prevent activation of  
14 the pump under specific circumstances ensuring that the pump does not generate  
15 excessive bladder pressures. These sensors can be placed anywhere along the length of  
16 either tube, including the extremes of a position at the site of pump attachment and a  
17 position at the tip of the tubing. Optionally, the two tubes can be integrated together into  
18 a single tubular member having two distinct lumens for ease of insertion.

19 **[0014]** The shunt for anchoring to the bladder wall may, in one variation,  
20 comprise a hollow, cylindrical column with flanges at either or both ends to provide  
21 secure anchorage in the bladder wall. The shunt may have an integrated mechanism to  
22 ensure uni-directional flow of fluid while preventing reflux of urine and other fluids back  
23 through the shunt. One variation of the shunt may provide a passive ball-valve

1 mechanism which allows for drainage of fluid into the bladder whenever a certain  
2 minimum threshold pressure is achieved at the collection site. Another variation may  
3 provide an active valve mechanism which allows for controlled drainage of fluid into the  
4 bladder whenever the valve is actuated.

5 **[0015]** The system can be made available in multiple configurations and designs  
6 for varying types and severity of fluid collections. For drainage of excess cerebrospinal  
7 fluid, for example, the tubing connecting the pump to the ventricle of the brain may be  
8 fabricated to be significantly longer than the tubing for chronic ascites which need only  
9 reach an adjacent peritoneal cavity.

10 **[0016]** The methods of insertion of the fluid management system may be based,  
11 in part, on the location of the fluid collection. On the other hand, the tubular member  
12 spanning to the bladder wall may be placed, e.g., cystoscopically or transabdominally,  
13 using minimally invasive procedures. The pump may be placed subcutaneously using  
14 interventional radiology techniques including radiographic imaging such as ultrasound.  
15 The inflow tubing connected to the pump, in one variation, may be tunneled  
16 subcutaneously to the site of drainage and the outflow tubing can be subcutaneously  
17 channeled to the bladder. Alternatively, the pump can be placed in the peritoneal cavity,  
18 or other bodily cavity, and activated remotely or set to operate independently based on  
19 pressure signals sensed from the fluid. In this variation, the pump may be tethered to an  
20 inductive charging coil for recharging or, if a battery with sufficient life is used, may  
21 carry its own independent power supply.

1   **[0017]**           The system may also optionally include controls to limit the operation of  
2   the pump and provide feedback to ensure that the pump is operating correctly. Thus the  
3   total fluid flow can be monitored and tightly controlled.

4                           **BRIEF DESCRIPTION OF THE DRAWINGS**

5   **[0018]**           Fig. 1 shows a cross-sectional view of a variation of a shunt device.

6   **[0019]**           Fig. 2 shows a cross-sectional view of an implanted shunt.

7   **[0020]**           Fig. 3 shows a cross-sectional view of the implanted shunt when the  
8   peritoneal fluid pressure is insufficient to open the valve.

9   **[0021]**           Fig. 4 shows a cross-sectional view in an illustration of an example of an  
10   insertion device within which the shunt can be implanted in the bladder wall.

11   **[0022]**           Figs. 5A to 5C show alternative variations of the fluid management system  
12   with differing valve types, differing valve positioning and differing number of valves.

13   **[0023]**           Figs. 6A and 6B show cross-sectional illustrations of an alternative  
14   variation of the system and a detail view of the shunt, respectively, in which an active,  
15   externally, or internally controlled valve is utilized.

16   **[0024]**           Fig. 7 shows a cross-sectional illustration of an alternative variation of the  
17   drainage system in which a pump may be included along the length of the tubing.

18   **[0025]**           Figs. 8A to 8C show illustrations of a few of the alternative variations of  
19   the drainage system in which the peritoneal cavity, the pulmonary space, and the  
20   ventricular space are able to be drained.

21   **[0026]**           Fig. 9 shows an illustrative magnetically-coupled variation of the drainage  
22   system with an illustration of an externally located drive.

- 1    **[0027]**        Figs. 10A to 10C show a variation of the drainage system in which the  
2    tubes and pump may be removably attachable allowing for increased ease of insertion.
- 3    **[0028]**        Fig. 11A shows an implantable pump variation having removably  
4    attachable tubing in the attached position.
- 5    **[0029]**        Fig. 11B shows a variation on an implantable pump which may have its  
6    moment forces generated by the pump balanced.
- 7    **[0030]**        Fig. 12A shows a variation of the drainage system having a single dual-  
8    lumen tube.
- 9    **[0031]**        Figs. 12B to 12G show additional variations of the single dual-lumen tube.
- 10   **[0032]**        Fig. 13 shows a magnetically-coupled variation of the pump and external  
11   drive in which the magnetic interaction is circumferential.
- 12   **[0033]**        Fig. 14 shows an illustration of an electromechanical variation of the  
13   system in which the implanted pump may be rechargeable.
- 14   **[0034]**        Fig. 15 shows an illustration of an electromechanical variation of the  
15   device in which the implanted pump may be placed in a non-subcutaneous position.
- 16   **[0035]**        Figs. 16A to 16C show illustration of a few of the possible uses of the  
17   drainage system in the drainage of chronic fluid collections in various regions of the  
18   body.
- 19   **[0036]**        Fig. 17 shows a variation of the drainage system which may be fluidly  
20   coupled to the vascular system.
- 21   **[0037]**        Fig. 18 shows another variation of the drainage system which may be  
22   coupled to a stomach or another portion of the gastro-intestinal system.



DETAILED DESCRIPTION OF THE INVENTION

**[0038]** The implantable fluid management system may comprise devices for facilitating the removal of fluid from a body region where drainage is desired. For instance, the devices disclosed herein may be utilized for chronic excess fluid drainage from one bodily cavity to a second bodily cavity, e.g., a urinary bladder. An implantable electromechanically powered and/or magnetically coupled vesicular pump may be utilized to permit assisted flow of the excess fluid collections into the bladder. This flow may be directed to be uni-directional through the system.

**[0039]** As can be seen in Fig. 1, a vesicular shunt or drain **1** may be utilized with the fluid management system for anchoring a tubing member to the wall of a urinary bladder. A further detailed description of the shunt and its applications may be seen in U.S. Application Serial No. 10/369,550 filed on February 21, 2003, which has been incorporated herein by reference above. Shunt or drain **1** may be implanted in the bladder wall **9**, as shown in Fig. 2, and can be configured to provide for uni-directional drainage of fluid into the bladder. In one variation, the shunt or drain **1** may comprise a flange or projection **2, 3** at each end of the shunt **1** to facilitate firmly anchoring the shunt **1** across the bladder wall **9**. Alternative variations of the shunt **1** may utilize other anchoring mechanisms, including, but not limited to, screw threading on the outside of shunt **1**, staples, sutures, adhesive compounds, one or more barbs, etc., and combinations thereof.

**[0040]** In one variation, the shunt **1** may be configured to define a lumen through the shaft of the device with a valving mechanism positioned within this lumen. For instance, a ball-valve **4** may be positioned to obstruct an inflow opening of the lumen. A

1    biasing element such as a spring 5 may be configured to provide a closing pressure  
2    against the ball-valve 4 such that the lumen remains shut until a minimum threshold  
3    pressure is developed by the fluid which may force the ball-valve 4 open or until a pump  
4    is actuated to open the valve 4. The inflow port of the shunt 1 may optionally include a  
5    porous mesh or filter 6 to allow for the free flow of fluid through shunt 1 while  
6    preventing the incarceration of tissues at the drainage site. Moreover, the mesh or filter 6  
7    may be configured to filter the fluid through a polymer to sequester components which  
8    may be present within the fluid, such as albumin and other proteins, while allowing the  
9    flow of fluids and ions across the semi-permeable membrane.

10    [0041]        As can be seen in the variation of Fig. 2, once a pressure of the collected  
11    peritoneal fluid 19 has built up, in this case within the peritoneal cavity 7, and exceeds  
12    the combined threshold force of the spring 5 and a pressure of the fluid-filled bladder  
13    cavity 8, the peritoneal fluid 19 may urge the ball-valve 4 open to then allow fluid flow  
14    into the bladder 8. Once the peritoneal fluid 19 has entered the bladder, the peritoneal  
15    fluid 19 may mix with the urine 20 and any other fluids which may be present. Once a  
16    sufficient amount of fluid 19 has passed through shunt 1 and the fluid pressure within the  
17    peritoneal cavity 7 falls below the threshold pressure of the spring 5, the ball-valve 4 may  
18    be urged shut to prevent further fluid flow through the shunt 1. The spring force exerted  
19    by the biasing element to shut the valve 4 within the shunt 1 may be varied depending  
20    upon the amount of fluid flow desired.

21    [0042]        If the combined pressure from the fluid pressure within the bladder 8 and  
22    the closing force of the spring 5 is greater than the pressure exerted by the collected fluid

1 within the peritoneal cavity 7, then the valve 4 will remain closed preventing reflux of  
2 urine and other fluids back into the peritoneal cavity 7, as depicted in Fig. 3.

3 **[0043]** The shunt 1 may be designed to be deployed transurethraly or  
4 transabdominally via an insertion device 10, such as that depicted in the variation of Fig.  
5 4. Various devices such as endoscopes, catheters, introducers, etc., may also be utilized  
6 as an insertion device 10 depending upon the patient anatomy and the location where the  
7 shunt 1 is to be placed. A specially configured insertion device 10 may define a cavity or  
8 channel within which the shunt 1 may be positioned for deployment within a patient. The  
9 variation shown in the figure may incorporate flexible flanges 2, 3 on one or both ends of  
10 the shunt 1. During delivery, one or both flanges 2, 3 may be configured in a low profile  
11 configuration and after delivery, one or both flanges 2, 3 may be configured to self-  
12 expand or reconfigure into a larger configuration. Accordingly, flanges 2, 3 may  
13 optionally be fabricated from spring steels, shape memory alloys and superelastic alloys  
14 such as nitinol, etc. Once the distal end of insertion device 10 has been brought into  
15 proximity or adjacent to the region of tissue where shunt 1 is to be inserted, the shunt 1  
16 may be urged out of insertion device 10 via a pusher or plunger, as shown in the figure.  
17 Alternatively, shunt 1 may be positioned upon the distal end of an insertion device and  
18 released into the tissue wall via a release mechanism.

19 **[0044]** A tubing member 11 may be attached to the inflow port of shunt 1. This  
20 tubing member 11 may be made such that it is sufficiently long enough to reach the  
21 region within the body where excess fluid collects. As shown in the illustrative drawings  
22 in Figs. 5A to 5C, tubing member 11 may have a perforated receptacle 12, as described in  
23 further detail below, through which the collected fluid may drain into the tubing 11.

1 Other methods for fluid transport may include, but are not limited to, conduits, catheters,  
2 saphenous arteries or vessels, artificial tubular grafts, etc.

3 **[0045]** In addition to the shunt 1 having a ball valve 4 in combination with the  
4 tubing member 11, other variations may utilize one or more valves of a variety of  
5 different types. For instance, passively-actuated valves, i.e., valves which are configured  
6 to automatically open and close without being actively actuated, such as the ball-valve 4  
7 shown in Fig. 5A and flapper valve 13 as shown in Fig. 5B. The flapper type valve 13  
8 may be positioned within shunt 1 near the outflow port, as shown in Fig. 5B, or it may  
9 also be positioned closer to the inflow port, as shown in Fig. 5C. An additional optional  
10 valve 14 may be incorporated into the tubing member 11 anywhere along the length of  
11 tubing 11. The types of valves disclosed are intended to be illustrative and is not  
12 intended to be limiting. Other variations of the valves are intended to be within the scope  
13 of this disclosure.

14 **[0046]** Alternatively, active valves, i.e., valves which may be configured to open  
15 and close via an actuation or sensing element, may also be utilized with the fluid  
16 management system. The use of active valves may be utilized for maintaining a tighter  
17 control of fluid drainage. For instance, Fig. 6A shows one variation of an active valve 15  
18 positioned within the lumen of shunt 1 in combination with the tubular member 11. Fig.  
19 6B shows a cross-sectional side view of the shunt 1 along having the active valve 15  
20 positioned within. Active valve 15 may be actuatable via a remotely located controller to  
21 open and shut upon receiving a signal. Alternatively, sensors positioned within the shunt  
22 1 or within the tubing 11 may provide a signal to the active valve 15 to open or shut  
23 according to the signal.

1   **[0047]**           In another variation, an electronic valve may be configured to become  
2   triggered via communication across the tissues of the human body through  
3   electromagnetic signals such as radio frequency, microwave, or other electromagnetic  
4   frequencies. Alternatively, pressure (patient-applied or otherwise) mechanical, magnetic,  
5   or other methods of communication may be utilized to signal allowing for drainage only  
6   at selected times. The valve of the device can take many shapes and the device can be  
7   manufactured from any of a variety of materials provided that they are biocompatible.

8   **[0048]**           The fluid management system may also be configured to incorporate a  
9   pump **16**, as shown in Fig. 7. Pump **16**, when placed subcutaneously, can be actuated to  
10   provide an active pumping mechanism with or without the use of passive or active  
11   valves, as described in further detail below. Pump **16** may be configured as a uni-  
12   directional pump to facilitate fluid transfer in a single direction. This uni-directional  
13   pump feature may be utilized in place of the valve or in combination with the valves.

14   **[0049]**           The patient may optionally perform maneuvers to help increase the  
15   pressure of any fluid which may be contained within the body cavity. For instance, the  
16   patient may bear down to increase intra-abdominal pressure to facilitate drainage of the  
17   peritoneal cavity. Alternatively, the patient may also wear or apply a girdle designed to  
18   increase abdominal pressure or apply a urethral catheter to decrease bladder pressure.

19   **[0050]**           The fluid management system may be configured to drain fluid collections  
20   from a variety of different regions within the body. For example, while the shunt **1** may  
21   be anchored within the bladder wall, the receptacle **12** may be placed, as described above,  
22   within the peritoneal cavity as shown in Fig. 8A. Another example is shown in Fig. 8B  
23   where the receptacle **17** may be positioned within the pulmonary space for draining

1 pulmonary effusions and Fig. 8C shows an example where the receptacle 18 may be  
2 positioned within the cerebrospinal region for draining excess cerebrospinal fluid. In  
3 another variation, a receptacle may be positioned within the pericardial region for  
4 draining pericardial effusions.

5 **[0051]** In yet another variation, the shunt, pump, or tubular devices may  
6 incorporate one or several anti-infective agents to inhibit the spread of infection between  
7 body cavities. Examples of anti-infective agents which may be utilized may include, e.g.,  
8 bacteriostatic materials, bacteriocidal materials, one or more antibiotic dispensers,  
9 antibiotic eluting materials, entrained radioisotopes, heating elements, bioactive plastics,  
10 surfaces which encourage epithelialization, and coatings which prevent bacterial  
11 adhesion, and combinations thereof.

12 **[0052]** Additionally, the devices may also incorporate anti-clogging agents.  
13 Examples of anti-clogging agents may include, e.g., active ultrasonic components, an  
14 inner and outer sleeve which, when actively agitated through coupling to the pump drive  
15 or through a flow driven mechanism, disrupts the inner lumen, surfaces which encourage  
16 epithelialization, enzyme eluting materials, enzyme eluting materials which specifically  
17 target the proteinaceous components of ascites, enzyme eluting materials which  
18 specifically target the proteinaceous and encrustation promoting components of urine,  
19 chemical eluting surfaces, an intermittent plunger mechanism, coatings which prevent  
20 adhesion of proteinaceous compounds, and combinations thereof. The anti-infective  
21 and/or anti-clogging agents may be infused through the devices via a reservoir contained,  
22 for instance, in the pump or in a separate reservoir. Alternatively, the agents may be  
23 integrated within or coated upon the surfaces of the various components of the system.

1   **[0053]**           Fig. 9 shows an illustrative detail view of another variation of the system  
2   of Fig. 7 above. As shown, fluid may be drawn up and carried away by the uptake tube  
3   **107**, which in this case, has been perforated to prevent blockage. Alternate variations  
4   may include an uptake screen at the terminus of the uptake tubing member **107**.  
5   Although multiple perforations or openings are shown in tubing member **107**, a single  
6   opening may also be defined at the terminal end of the tubing **107** or along the length of  
7   the tubing **107**. As mentioned above, the uptake tubing **107** may also include, but is not  
8   limited to, conduits, catheters, saphenous arteries or vessels, artificial tubular grafts, etc.  
9   The tubing **107** may be positioned where the excess fluid typically collects within the  
10   cavity. Tubing **107** may simply be left within the cavity or it may be anchored to a tissue  
11   wall via any number of methods for fastening the tubing **107**, e.g., sutures, staples,  
12   clamps, adhesives, etc.

13   **[0054]**           The uptake tubing **107** leads to the pump **101**, which may be used to  
14   actively pump or urge the fluid from the uptake tubing **107** and through the outflow tube  
15   **108** and into the bladder **110**. In this variation, an optional bladder anchor or shunt **109**  
16   may be utilized to secure the distal end or portion of outflow tube **108** and prevent  
17   detachment of tubing **108** during bladder contraction. The bladder anchor or shunt **109**  
18   may be configured in any one of the variations as described above for the shunt **1**.

19   **[0055]**           The pump **101**, can be powered and operated by electromechanical forces  
20   or magnetic coupling. The pump **101** may be placed under the skin **111** in either the  
21   subcutaneous space **112** or in the musculature of the abdominal wall **113**. The pump **101**  
22   may be configured as a peristaltic pump, but may also be a gear-pump, turbine-pump,  
23   impeller-pump, radial-flow-pump, centrifugal-pump, piston-pump, or any other suitable

1 pump type. Ideally, the pump **101** design ensures uni-directional operation. Moreover,  
2 the pump **101** may be configured to incorporate a pulsatile or oscillating mechanism  
3 within the pump **101** to aid in jarring free any materials from collecting or becoming  
4 encrusted to thereby prevent the pump **101** or tubing from clogging. However, valves  
5 may be configured to ensure uni-directional operation. The pump **101** is preferably  
6 enclosed in a housing, shroud or casing **125** made of any suitable biocompatible material.

7 **[0056]** Also enclosed in the pump housing **125**, in this particular variation, is the  
8 magnetically-coupled drive. One, two, or more magnets **103** may be provided to operate  
9 the pump **101**. A separate control module **116** which is remotely located from the  
10 implanted pump **101** may be used to drive external magnets **105** located within the drive  
11 unit **102** or magnets **105** may be used to provide an oscillating or alternating  
12 electromagnetic field to correspondingly couple through the skin **111** with a magnetic  
13 field of the implanted magnets **103** located within the pump **101**. By rotating or  
14 oscillating the magnets **105** in the drive unit **102**, the implanted magnets **103** are  
15 stimulated or urged to move, thereby transferring their kinetic force to operate the pump  
16 **101**. While Fig. 9 shows a drive unit **102** with a motor and a linkage, any magnetic field  
17 capable of causing or urging the pump magnets **103** to rotate could be used to operate the  
18 pump. Furthermore, in order to reduce the torque seen by tissues adjacent to the  
19 implanted pump, the pump may utilize a gear mechanism whereby the external drive  
20 rotates or oscillates two elements in opposite direction thereby canceling any torques  
21 generated. Alternatively, the pump **101** could be electromechanically powered through  
22 an implanted battery with external activating and/or monitoring without the requirement  
23 for magnetic coupling in which case drive unit **102** may be configured to function as a



1 remote switch for activating the pump **101**. One or more sensors may be integrated into  
2 the implanted pump **103** for detecting a variety of fluid and/or pump parameters. For  
3 instance, Fig. 9 shows at least one sensor **104** integrated within implanted pump **101**. A  
4 corresponding sensor **106** may be built into the interface of the external drive **102**. Both  
5 sensors **104** and **106** may be positioned within their respective units such that when the  
6 drive **102** is optimally aligned with implanted pump **101**, the sensors **104**, **106** may  
7 indicate to the physician or patient that the pump **101** and drive **102** are optimally  
8 engaged and able to efficiently transfer power and/or information. The drive **102** or some  
9 other indicator may be used to convey the presence of an optimal engagement to the  
10 physician or patient through a variety of methods, for instance, a visual message or  
11 indicator signal such as a light or audible signal may be initiated once the sensors **104**,  
12 **106** have been aligned. These sensors **104**, **106** may also transfer information from the  
13 pump **101** to the drive **102**, and/or from the drive **102** to the pump **101**, during operation  
14 to monitor fluid pressures and/or fluid flows. Alternatively, additional magnets could  
15 also be utilized to anchor the pump **101** to the drive **102** against rotational forces  
16 generated during the power transfer operation.

17 **[0057]** The individual implantable components of the system are shown in detail  
18 in Figs. 10A to 10C. In Fig. 10A, the outflow tubing **108** is shown in one variation in its  
19 insertion trocar **117**. Also illustrated are the bladder anchor **109** and an optional  
20 removably attachable port **118** which may be designed to couple with an insertion port  
21 **120** on the pump **101**. Fig. 10B illustrates one variation of the inflow drainage tubing  
22 **107** in an insertion trocar **117** with an optional removably attachable port **119**. Although  
23 these variations show the tubing **107**, **108** positioned within insertion trocars **117** for

1 deployment within a patient, the tubing **107**, **108** may be implanted through various other  
2 methods as may be contemplated by one of ordinary skill in the art.

3 **[0058]** Fig. 10C illustrates one variation of the implantable pump **101** with tubing  
4 detached. The pump **101** is illustrated with anchors **121** to resist rotational forces  
5 generated with pump use. The pump housing **125** may be anchored by barbed insertion  
6 pins **121** and/or materials designed to promote fibrotic ingrowth for anchoring the pump  
7 **101** within the muscle **113** or subcutaneous space **112**. Alternative variations of the  
8 pump device **101** may use other anchoring mechanisms, e.g., screw threading defined on  
9 outside surfaces of pump **101**, staples, sutures, adhesive compounds, a porous solid  
10 promoting interstitial cell growth, one or more pins designed to be inserted into the  
11 abdominal wall, etc., and combinations thereof. In the variation shown, the tubing **107**,  
12 **108** and pump **101** are separate components and may be placed individually. For instance,  
13 the two tubes **107**, **108** may be first inserted through a single incision in the skin and  
14 placed in their approximate positions within the patient. The pump **101** may then be  
15 inserted through the incision and attached to both tubes **107**, **108** and secured at the  
16 implantation site. Alternatively, the tubing **107**, **108** may be attached to the pump **101**  
17 prior to implantation or during manufacture and the entire system may be implanted as a  
18 single system.

19 **[0059]** Fig. 11A illustrates the pump **101** and tubing **107**, **108** of Figs. 10A to 10C  
20 in which the tubing **107**, **108** has been attached to the corresponding outflow and inflow  
21 ports of pump **101** at the junctures of tubing port **118** to pump **120** and tubing port **119** to  
22 pump **120**. Also shown are optional sensors **122**, **124** on the ends of the inflow tubing  
23 **107** and outflow tubing **108**, respectively. One or both of these sensors **122**, **124** may be

1 configured to sense any one of a number of fluid parameters. For instance, one or both  
2 sensors **122, 124** may detect fluid pressures and/or various chemical parameters such as  
3 pH of the fluid, or the presence of certain chemicals, etc. One or both sensors **122, 124**  
4 may also be configured to provide positive and/or negative feedback to the control  
5 mechanism, such as the externally located drive unit **102** or an integrated controller  
6 located within the pump **101**, in the control of fluid flows. Although both sensors **122,**  
7 **124** are shown located at the terminal ends of tubing **107, 108**, respectively, they may  
8 optionally be located anywhere along the lengths of their respective tubes **107, 108**, if  
9 desired or necessary.

10 **[0060]** Fig. 11B shows a cross-sectional view of another variation of pump **101**  
11 which may be utilized to effectively eliminate any excessive movement which may be  
12 imparted by torquing forces generated by the pump **101**. After pump **101** has been  
13 implanted within a patient, it is generally desirable to inhibit movement of the pump **101**  
14 within the body. This may be accomplished through a variety of methods, such as  
15 securely anchoring the pump **101** to the surrounding tissue. This pump variation may  
16 also be configured to reduce any torque which may be seen by tissues adjacent to the  
17 implanted pump **101**. This may be accomplished, in part, by utilizing at least two  
18 counter-rotating or counter-oscillating elements within the pump **101** which may rotate or  
19 oscillate during pumping such that oppositely generated moments or rotational moments  
20 effectively cancel out or balance each other. As seen in this variation, if a driver unit,  
21 such as that described above, were activated to rotate element **138** in a first direction, a  
22 first rotational moment **141** is generated. This moment **141**, if unbalanced, may impart  
23 forces from the pump **101** to the surrounding tissue potentially resulting in damage to the

1 tissue. Element **138** may be rotationally coupled to a gear box **140** which may be  
2 configured to reverse the imparted direction of rotation such that element **139**, which is  
3 also rotationally coupled to gear box **140**, is compelled to rotate in an opposite direction  
4 from element **138** thus creating a rotational moment **142**. The opposite rotational  
5 moments **141**, **142** may effectively balance or cancel one another such that the net force  
6 imparted by the pump **101** to the surrounding tissue is minimized, potentially to a zero  
7 load. The counter-rotating or counter-oscillating (depending upon the type of pump  
8 utilized) elements within a pump may be balanced in mass and in configuration in any  
9 number of ways to optimize the resulting effect on the pump, depending upon the desired  
10 effects.

11 **[0061]** Fig. 12A illustrates one variation of the fluid management system in which  
12 both inflow **107** and outflow **108** tubing share a common wall. This arrangement may be  
13 utilized ideally for the peritoneal fluid draining design because the bladder **110** and  
14 peritoneal cavity **115** share a common wall which facilitates the insertion of a single dual-  
15 lumen tube. Also shown is flange **123** which can be utilized to prevent insertion of the  
16 inflow tubing **107** into the bladder **110** in the case of the single-puncture placement.  
17 Moreover, any one of the shunt **1** variations described above may be utilized with this  
18 variation.

19 **[0062]** Figs. 12B and 12C show cross-sectional side and end views, respectively,  
20 of the tubing variation of Fig. 12A. As shown, inflow tubing **107** and outflow tubing **108**  
21 may share common wall **133**, which may be reinforced to maintain the structural integrity  
22 of the tubing. The inflow tubing **107** may define one or a plurality of openings **134** for  
23 drawing the fluid within tubing **107**. Openings **134** may be defined along just a portion

1 of tubing **107** or it may be defined along a majority of the length of tubing **107** depending  
2 upon the desired application. In operation, the fluid within the body cavity may be drawn  
3 into tubing **107** through openings **134** and drawn into pump **103**. The fluid may then be  
4 passed through outflow tubing **108** in the opposite direction as the fluid flowing through  
5 inflow tubing **107** and subsequently into the bladder **110**. Figs. 12D and 12E show  
6 another variation of tubing **107'** and **108'** in which both tubes are formed from a single  
7 extrusion **135**. In this variation, tubing **107'** may define one or a plurality of openings  
8 **134**. Figs. 12F and 12G show cross-sectional side and end views of yet another variation  
9 of a single-tube dual-lumen variation in which outflow tubing **108''** may be coaxially  
10 positioned within inflow tubing **107''**. In this variation, openings **134** may be defined  
11 along a length of inflow tubing **107''** while outflow tubing **108''** may remain intact.

12 **[0063]** Both inflow and outflow tubing, or just one of the tubes, may be  
13 reinforced along a portion of its length or along its entire length. Reinforcement of the  
14 tubing may be accomplished via ribbon or wire braiding or lengths of wire or ribbon  
15 embedded or integrated within or along the tubing. The braiding or wire may be  
16 fabricated from metals such as stainless steels, superelastic metals such as nitinol, or from  
17 a variety of suitable polymers.

18 **[0064]** Fig. 13 illustrates one variation of the pump device in which the magnetic  
19 coupling mechanism employed allows for circumferential interaction. As shown, the  
20 pump **101** may be implanted under the skin **111** yet close to the surface such that the  
21 pump magnets **103** may be positioned within the inner diameter of, and/or in the same  
22 plane as, the external drive magnets **105**. The arms **127** of the drive unit may protrude to  
23 define a circumferential cavity for receiving the implanted pump **101** and the overlying

1 skin **111** within this channel. The design of the holding arms **127** may be blunted to  
2 prevent excessive pressure from being exerted upon the skin **111** over the site of  
3 insertion. In this variation, the driveshaft **126** is shown which transfers power to the  
4 magnet holding arm **127** of the drive. This design can also employ one or several pump  
5 anchors **121**, sensors **104**, **106** and/or other features and combinations of the pump and  
6 tubing.

7 **[0065]** Figs. 14 and 15 illustrate non-magnetically powered pumps in which the  
8 implanted pump may be powered by a battery or other implantable power source. In this  
9 instance the pump **101** may communicate with the external interface **116** using radiowave  
10 or electromagnetic signal generators and receivers **128**, **129** to transfer information and/or  
11 activation signals. This pump **101** can be placed subcutaneously (as shown in Fig. 14) or  
12 in any other region suitable for implantation (for instance, the pump **101** of Fig. 15 may  
13 be implanted directly within the peritoneal cavity) so long as it can communicate with the  
14 external component **116**. The pump can also be internally controlled using the sensors  
15 **122**, **124** to determine when to activate the pump. These variations may be configured so  
16 that the physician or patient may be able to intervene using the external control  
17 mechanism **116** in order to prevent the operation of the pump **101** in undesirable  
18 circumstances. For example, if the sensors detect negative feedback, the physician and/or  
19 patient may activate the pump **101** using the external controls **116** at their discretion. The  
20 controls, though, may be easily programmed to incorporate various parameters such as a  
21 maximum drainage per day and simple drainage controls such as no drainage when the  
22 bladder exceeds a certain pressure. The pump **101** can also be programmed to be

1 activated under certain circumstances, e.g., once the peritoneal pressure sensor **122**  
2 experiences a pressure above a certain threshold.

3 **[0066]** The device may be designed to drain a variety of different fluid collections  
4 including, but not limited to, the excess fluid within the peritoneal cavity, as shown in  
5 Fig. 16A, pulmonary effusions, as shown in Fig. 16B, and excessive cerebrospinal fluid,  
6 as shown in Fig. 16C. These figures show the bladder anchor **109**, the outflow tube **108**,  
7 the pump **101**, the inflow tube **107**, and the drainage ports for the peritoneal **130**, pleural  
8 **131** and cerebrospinal **132** drainage sites, although other variations utilizing different  
9 features, such as the single tube, dual-lumen tubing described above may be substituted  
10 in further variations. Moreover, drainage from other regions of the body using the system  
11 and variations thereof are contemplated, such as application for drainage of pericardial  
12 effusions. It is important to note that any feature of the present invention can be  
13 incorporated into any these designs.

14 **[0067]** The housing, shroud or casing **125** of the pump can take many shapes and  
15 the pump housing **125** can be manufactured from any of a variety of biocompatible  
16 materials. Alternatively, the pump housing **125** may incorporate anti-infective  
17 components or agents in order to prevent the spread of infection between the body  
18 cavities. Such anti-infective components or agents may include, e.g., bacteriostatic  
19 materials, bacteriocidal materials, one or more antibiotic dispensers, antibiotic eluting  
20 materials, entrained radioisotopes, heating elements, bioactive plastics, surfaces which  
21 encourage epithelialization, coatings which prevent bacterial adhesion, etc., and  
22 combinations thereof. Alternatively, the device may also incorporate anti-clogging  
23 components, e.g., active ultrasonic components, surfaces which encourage

1 epithelialization, enzyme eluting materials, chemical eluting surfaces, coatings which  
2 prevent adhesion of proteinaceous compounds, etc., and combinations thereof.

3 **[0068]** The device has been designed to allow for minimally invasive placement,  
4 ideally through the use of non-invasive radiographic imaging tools such as abdominal  
5 ultrasound. Placement of the fluid management system may be facilitated by filling the  
6 bladder **110** and using ultrasound to locate this space; the outflow tubing **108** can then be  
7 placed through a small incision and a simple puncture. The inflow tubing **107** can also be  
8 placed in a similar manner using subcutaneous tunneling of the tubing and ultrasound  
9 guidance. Once the tubing has been placed, the outflow tubing **107** and the inflow tubing  
10 **108** may then be attached to the pump **101** at the insertion sites. The pump **101** may then  
11 be set into its site of implantation (for instance, in the subcutaneous space) after which  
12 the wound is closed and allowed to heal.

13 **[0069]** Another application for the fluid management system may be seen in Fig.  
14 17, which shows outflow tubing **108** fluidly coupled in a fluid-tight seal to the vasculature  
15 **136** of the patient. The fluid collected through inflow tubing **107** may be urged via pump  
16 **101** through outflow tubing **108** and passed into the vasculature **136** via an anastomotic  
17 connection at one of any number of suitable locations along the vasculature. In such a  
18 variation, the outflow tubing **108** may be a saphenous vein or artery. The anastomotic  
19 connection between tubing **108** and the vasculature is preferably a fluid-tight seal and  
20 may be accomplished through any variety of methods as known to one of skill in the art.

21 **[0070]** Yet another variation is shown in Fig. 18, which shows outflow tubing **108**  
22 fluidly connected to a stomach **137** of the patient. The collected fluid may be passed into  
23 the stomach **137** through use of the shunt described above or through another anastomotic



1 connection to allow for the absorption of any additional nutrients which may be present  
2 in the excess fluid. The fluid urged into the stomach may then be passed through the  
3 gastro-intestinal system of the patient and eventually voided from the body. Although  
4 this example shows fluid connection to the stomach **137**, outflow tubing **108** may  
5 alternatively be coupled to other suitable regions of the gastro-intestinal tract, such as  
6 regions of the small and large intestinal tracts.

7 **[0071]** While the device is primarily contemplated for use in human patients, the  
8 invention will also have veterinary uses or product development purposes in equine,  
9 bovine, canine, feline, and other mammalian species.

10 **[0072]** The applications of the devices and systems discussed above are not  
11 limited to certain treatments, but may include any number of other maladies.  
12 Modification of the above-described methods for carrying out the invention, and  
13 variations of the mechanical aspects of the invention that are obvious to those of skill in  
14 the arts are intended to be within the scope of the claims. Moreover, various  
15 combinations of aspects between examples is also contemplated and is considered to be  
16 within the scope of this disclosure.

17